EUVIMEDEUVIMED entdecken
Crossref

APOC1 inhibit NKTCL doxorubicin sensitivity by promoting mitophagy

Sa Xiao, Jing Kuang, Jiamei Yang, Haili Wang, Yuanyuan Sun, Haipeng Zhang, Zhongyu Zhang, Mengyuan Shi, Kai Qi, Miao Jiang, Yanyan Zhang, Qingjiang Chen iD und 1 weitere

IUBMB Life · 2025

DOI: 10.1002/iub.2942 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IUBMB Life, 2025. Verfasst von Sa Xiao und 12 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, People's Republic of China. Hauptthemen laut MEDLINE: Mitophagy, Drug Resistance, Neoplasm, Doxorubicin. Die Arbeit nennt 24 Literaturangaben. Gefördert von: the Henan Provincial Science and Technology Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NKTCL is a highly aggressive malignant tumor, especially prevalent in the southern regions of China. Although chemotherapy regimens based on ADM have achieved certain therapeutic effects in early treatment, the issue of ADM resistance severely limits the therapeutic efficacy and makes it difficult to improve patient survival rates. Our research results indicate that the expression level of APOC1 is closely related to the sensitivity of NKTCL cells to ADM. The upregulation of APOC1 may promote mitophagy, clear damaged mitochondria, stabilize the intracellular environment, and enhance the tolerance of tumor cells to ADM. Furthermore, APOC1 may further affect the formation of mitophagy and drug resistance by activating specific signaling pathways, such as the STAT3 signaling pathway. Animal experiments further confirm the conclusions of in vitro experiments, showing that APOC1 regulates mitophagy through p‐STAT3 Tyr705 , thereby promoting the drug resistance of NKTCL. These findings provide a new perspective for the development of novel therapeutic strategies targeting APOC1 and its associated signaling pathways, which may help overcome the issue of ADM resistance in NKTCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitophagyDrug Resistance, NeoplasmDoxorubicinHumansAnimalsMiceSTAT3 Transcription FactorSignal TransductionGene Expression Regulation, NeoplasticCell Line, TumorXenograft Model Antitumor AssaysMitochondriaAntibiotics, AntineoplasticMice, Inbred BALB C

Stichwörter der Autor:innen

ADM resistanceAPOC1MitophagyNKTCLSTAT3

Substanzen

DoxorubicinSTAT3 Transcription FactorSTAT3 protein, humanAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • The First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, People's Republic of China.
  • The Second Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, People's Republic of China.
  • Zhengzhou Seventh People's Hospital, Guancheng, Zhengzhou, Henan Province, People's Republic of China.

ORCID-Profile: Qingjiang Chen

Förderung

  • the Henan Provincial Science and Technology Research Project

Zitieren

APA

Xiao, S., Kuang, J., Yang, J., Wang, H., Sun, Y., Zhang, H., Zhang, Z., Shi, M., Qi, K., Jiang, M., Zhang, Y., Chen, Q., & Zhang, X. (2025). APOC1 inhibit NKTCL doxorubicin sensitivity by promoting mitophagy. IUBMB Life. https://doi.org/10.1002/iub.2942

Vancouver

Xiao S, Kuang J, Yang J, Wang H, Sun Y, Zhang H, et al. APOC1 inhibit NKTCL doxorubicin sensitivity by promoting mitophagy. IUBMB Life. 2025. doi:10.1002/iub.2942

BibTeX
@article{Xiao2025,
  author = {Xiao, Sa and Kuang, Jing and Yang, Jiamei and Wang, Haili and Sun, Yuanyuan and Zhang, Haipeng and Zhang, Zhongyu and Shi, Mengyuan and Qi, Kai and Jiang, Miao and Zhang, Yanyan and Chen, Qingjiang and Zhang, Xudong},
  title = {APOC1 inhibit NKTCL doxorubicin sensitivity by promoting mitophagy},
  journal = {IUBMB Life},
  year = {2025},
  doi = {10.1002/iub.2942}
}
Kostenlos starten →